2013-05-02 01:01:59 - New Pharmaceuticals research report from GlobalData is now available from Fast Market Research
GlobalData has released its new PharmaPoint Drug Evaluation report, "Evista (Osteoporosis) - Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the 'gold-standard' bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly's blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift
away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.
Full Report Details at
- www.fastmr.com/prod/591922_evista_osteoporosis_forecast_and_mark ..
These changes in the osteoporosis market will be reflected in the slow growth during the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%.
Eli Lilly's Evista (raloxifene hydrochloride) is an orally-administered SERM indicated for the treatment of osteoporosis in postmenopausal women. Evista is a benzothiophene-derived SERM that works in several ways on bone. It primarily binds to estrogen receptors (ERs) that activate specific DNA sequences known as raloxifene responding elements (RRE). These elements are responsible for the synthesis of specific cell proteins that create estrogen agonist activity, which blocks osteoclast differentiation downstream. This, in turn, keeps osteoclasts from binding to bone effectively and decreases bone resorption. Secondly, activation of raloxifene-ligand binding has been shown to decrease osteoclastic resorption activity by 50%, decrease IL-6 production, and decrease tumor necrosis factor-alpha (TNF-a) production by 30%, which helps decrease bone resorption (Gianni et al., 2004). In 2007, Evista was approved by the Food and Drug Administration (FDA) to treat breast cancer, extending its US patent protection until 2014.
Note: This is upcoming report and will be delivered within 24 hrs of the purchase (excluding weekends).
* Overview of Osteoporosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Evista including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Evista for the top nine countries from 2012 to 2022.
* Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, China and India
Reasons to buy
* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Osteoporosis
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Evista performance
* Obtain sales forecast for Evista from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, China and India)
Report Table of Contents:
1 Table of Contents
1.1 List of Tables
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.3 Risk Factors
3.1.4 Quality of Life
4 Disease Management
4.1 Treatment Overview
4.1.1 Diagnosis and Referral
4.1.2 Treatment Guidelines
4.1.3 Disease Management
5 Competitive Assessment
5.2 Strategic Competitor Assessment
6 Evista (raloxifene hydrochloride)
6.4 SWOT Analysis
7.4 Forecasting Methodology
7.4.1 Diagnosed Osteoporosis Patients
7.4.2 Percent Drug-Treated Patients
7.4.3 General Pricing Assumptions
7.4.4 Individual Drug Assumptions
7.4.5 Generic Erosion
7.5 Physicians and Specialists Included in this Study
7.5.1 About the Authors
7.5.2 Global Head of Healthcare
7.6 About GlobalData
7.7 Contact Us
List of Tables
1.1 List of Tables
Table 1: Etiology of Primary Osteoporosis
Table 2: Etiology of Secondary Osteoporosis
Table 3: Symptoms of Osteoporosis
Table 4: Diagnostic Tests for Osteoporosis
Table 5: T-Score Ranges for Determination of BMD
Table 6: Treatment Guidelines for Osteoporosis
Table 7: Most Prescribed Drugs for Osteoporosis by Therapeutic Class in the Global Markets, 2012
Table 8: Leading Treatments for Osteoporosis, 2012
Table 9: Product Profile - Evista
Table 10: Evista SWOT Analysis, 2012
Table 11: Global Sales Forecasts ($m) for Evista, 2012-2022
Table 12: Number of High-Prescribing Physicians Surveyed
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.